文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

晚期HIV感染者的猴痘:全球病例系列

Mpox in people with advanced HIV infection: a global case series.
PubMed 文献 · Lancet · 2023-02-21
一句话结论在CD4<350个/mm³的HIV感染者中,猴痘可表现为坏死性重症,住院者病死率25%,所有死亡均发生于CD4<200个/mm³者。

该全球病例系列纳入19个国家382例确诊猴痘的HIV成人(CD4<350个/mm³或CDC C期),中位CD4 211个/mm³,51%病毒载量检测不到。CD4<100个/mm³者较>300个/mm³者更常见坏死性皮损(54% vs 7%)、肺部受累(29% vs 0%)及继发感染和脓毒症(44% vs 9%)。382例中107例(28%)住院,住院者27例(25%)死亡,全部死亡者CD4<200个/mm³;CD4<200个/mm³者中高HIV病毒载量者死亡更多。21例(25%)在启动或重启ART后疑似猴痘相关免疫重建炎症综合征,其中12例(57%)死亡。作者认为,晚期免疫抑制下的坏死性猴痘表现类似艾滋病定义性疾病。

要点

  • CD4<100个/mm³者坏死性皮损54%、肺部受累29%、继发感染和脓毒症44%,均高于CD4>300个/mm³者的7%、0%、9%。
  • 382例中107例(28%)住院,住院者27例(25%)死亡;所有死亡均发生于CD4<200个/mm³者。
  • CD4<200个/mm³者中,高HIV病毒载量者死亡更多。
  • 启动或重启ART后21例(25%)疑似猴痘相关免疫重建炎症综合征,其中12例(57%)死亡。
  • 仅62例(16%)接受tecovirimat,7例(2%)接受西多福韦或布林西多福韦;3例实验室确认tecovirimat耐药。

适用人群与场景

  • 18岁以上HIV感染者,CD4细胞计数<350个/mm³;在CD4计数不能常规检测的环境中,临床分类为美国CDC C期。
  • 2022年5月11日至2023年1月18日期间确诊猴痘病例。

诊断标准与关键阈值

  • HIV感染且CD4细胞计数<350个/mm³,或临床分类为美国CDC C期。

处置流程与药物剂量

  • 62例(16%)接受tecovirimat治疗;7例(2%)接受西多福韦或布林西多福韦治疗。
  • 21例(25%)在启动或重启ART后疑似猴痘相关免疫重建炎症综合征。

红旗征与不能漏的情况

  • CD4<100个/mm³者出现坏死性皮肤病变(54%)、肺部受累(29%,偶见结节)、继发感染和脓毒症(44%)。
  • CD4<200个/mm³者死亡风险高,尤其高HIV病毒载量者。
  • 启动或重启ART后疑似免疫重建炎症综合征者死亡风险高(21例中12例死亡,57%)。

研究设计与关键结果

  • 全球病例系列纳入19个国家382例确诊猴痘的HIV成人:367例顺性别男性、4例顺性别女性、10例跨性别女性;中位年龄35岁(IQR 30-43)。
  • 确诊猴痘时,349例(91%)已知HIV感染;349例中228例(65%)坚持ART;382例中32例(8%)合并机会性感染。
  • 中位CD4计数211个/mm³(IQR 117-291);85例(22%)CD4<100个/mm³,94例(25%)CD4 100-200个/mm³;193例(51%)病毒载量检测不到。
  • CD4<100个/mm³者较CD4>300个/mm³者更常见坏死性皮肤病变(54% vs 7%)、肺部受累(29% vs 0%)、继发感染和脓毒症(44% vs 9%)。
  • 382例中107例(28%)住院,住院者27例(25%)死亡;所有死亡均发生于CD4<200个/mm³者;CD4<200个/mm³者中高HIV病毒载量者死亡更多。
  • 启动或重启ART后21例(25%)疑似猴痘相关免疫重建炎症综合征,其中12例(57%)死亡。
  • 62例(16%)接受tecovirimat,7例(2%)接受西多福韦或布林西多福韦;3例实验室确认tecovirimat耐药。

证据类型、等级与局限

  • 研究类型:全球病例系列(描述性分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对CD4<200个/mm³的HIV感染者,猴痘可能表现为坏死性重症且死亡风险高,应作为重症监测对象。
  • 启动或重启ART后出现疑似免疫重建炎症综合征者,死亡风险高(21例中12例死亡,57%)。
  • 作者认为,晚期免疫抑制下的坏死性猴痘表现类似艾滋病定义性疾病。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: People living with HIV have accounted for 38-50% of those affected in the 2022 multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell counts and similar outcomes to those without HIV. Emerging data suggest worse clinical outcomes and higher mortality in people with more advanced HIV. We describe the clinical characteristics and outcomes of mpox in a cohort of people with HIV and low CD4 cell counts (CD4 <350 cells per mm3).

METHODS: A network of clinicians from 19 countries provided data of confirmed mpox cases between May 11, 2022, and Jan 18, 2023, in people with HIV infection. Contributing centres completed deidentified structured case report sheets to include variables of interest relevant to people living with HIV and to capture more severe outcomes. We restricted this series to include only adults older than 18 years living with HIV and with a CD4 cell count of less than 350 cells per mm3 or, in settings where a CD4 count was not always routinely available, an HIV infection clinically classified as US Centers for Disease Control and Prevention stage C. We describe their clinical presentation, complications, and causes of death. Analyses were descriptive.

FINDINGS: We included data of 382 cases: 367 cisgender men, four cisgender women, and ten transgender women. The median age of individuals included was 35 (IQR 30-43) years. At mpox diagnosis, 349 (91%) individuals were known to be living with HIV; 228 (65%) of 349 adherent to antiretroviral therapy (ART); 32 (8%) of 382 had a concurrent opportunistic illness. The median CD4 cell count was 211 (IQR 117-291) cells per mm3, with 85 (22%) individuals with CD4 cell counts of less than 100 cells per mm3 and 94 (25%) with 100-200 cells per mm3. Overall, 193 (51%) of 382 had undetectable viral load. Severe complications were more common in people with a CD4 cell count of less than 100 cells per mm3 than in those with more than 300 cells per mm3, including necrotising skin lesions (54% vs 7%), lung involvement (29% vs 0%) occasionally with nodules, and secondary infections and sepsis (44% vs 9%). Overall, 107 (28%) of 382 were hospitalised, of whom 27 (25%) died. All deaths occurred in people with CD4 counts of less than 200 cells per mm3. Among people with CD4 counts of less than 200 cells per mm3, more deaths occurred in those with high HIV viral load. An immune reconstitution inflammatory syndrome to mpox was suspected in 21 (25%) of 85 people initiated or re-initiated on ART, of whom 12 (57%) of 21 died. 62 (16%) of 382 received tecovirimat and seven (2%) received cidofovir or brincidofovir. Three individuals had laboratory confirmation of tecovirimat resistance.

INTERPRETATION: A severe necrotising form of mpox in the context of advanced immunosuppression appears to behave like an AIDS-defining condition, with a high prevalence of fulminant dermatological and systemic manifestations and death.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023. PMID: 36828001. doi:10.1016/S0140-6736(23)00273-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。